The expression of EGFR, HER-2, HER-3 and HER-4 reported in the literature for ovarian cancer exhibits wide variation ranging from 9–90%, 6.4–52%, 16–69%, and 65–90% of the cases examined respectively, with EGFRvIII expression being rare [52–59]. This evidence concerns the gene ERBB2 and ovarian carcinoma.